Articles Tagged With: HIV
-
An Old Pro Stays in the Fight Against Needlesticks
At age 78, with more than 50 years of clinical consultation and research on needlesticks, sharps injuries, and medical waste, Terry Grimmond, FASM, BAgrSc, GrDpAdEdTr, says he retired at the end of 2023 but is still winding his career down with a few final projects.
-
PEP Clock Ticking After Sharps Injury
Infection preventionists involved in post-exposure prophylaxis (PEP) for potential human immunodeficiency virus needlesticks should know the clock is ticking after injury follow-up begins. Such needlesticks certainly are a rare event, but the risk of seroconversion is not zero. A call to the National Clinician Consultation Center PEP line could be in order.
-
Beliefs About Women’s Virtue and Chastity May Play a Role in Latina Risk Behaviors
The authors of a recent study revealed that endorsement of certain marianismo beliefs, related to women acting virtuous and chaste, may promote abstinence, but also are associated with sexual risk behaviors.
-
HIV Needlestick: Low Risk, High Anxiety
Worst-case scenario: a healthcare worker experiences a needlestick and is exposed to the blood of an HIV-positive patient. All things considered, there is a less than 1% chance that the healthcare worker will acquire HIV from a known positive needlestick. Despite those odds, many healthcare workers do not feel particularly lucky right after a needlestick.
-
Patients with HIV Support Clinic-Based Contraceptive Care by Pharmacists
New research shows that women with HIV infection and who happen to be high users of contraception support receiving contraception prescriptions from pharmacists.
-
Adjunctive Dexamethasone Is Not Beneficial for HIV Patients with Tuberculous Meningitis
A randomized, placebo-controlled clinical trial in human immunodeficiency virus-positive adults with tuberculous meningitis found no benefit for adjunctive dexamethasone in survival or risk of neurologic immune reconstitution inflammatory syndrome (IRIS). Side effects were similar to placebo.
-
Superinfection of Hepatitis B and Hepatitis D on the Horizon
Called a satellite virus, hepatitis delta virus (HDV) is making an outsized impact on liver disease and cancer worldwide. HDV only appears alongside a hepatitis B infection, and people living with HIV infection are particularly at risk of the disease.
-
Major Cardiovascular Event Risk Reduction with Pitavastatin in Patients Living with HIV
Among participants living with HIV who are at low-to-moderate risk for cardiovascular disease, those who received pitavastatin were 35% less likely to experience a major adverse cardiovascular event over a follow-up of approximately five years vs. those who received placebo.
-
Major Cardiovascular Event Risk Reduction with Pitavastatin in People Living with HIV
A large randomized, controlled trial (REPRIEVE) conducted by Grinspoon and colleagues showed that in participants living with human immunodeficiency virus (HIV) who are at low-to-moderate risk for cardiovascular disease, those who received pitavastatin had a 35% lower risk of experiencing a major adverse cardiovascular event over a follow-up of approximately five years than those who received placebo.
-
Long-Term Successful Virological Suppression with Dolutegravir Monotherapy in the EARL-SIMPLIFIED Trial
Dolutegravir monotherapy was demonstrated to be non-inferior as compared with combination antiretroviral therapy in EARLY-SIMPLIFIED, a randomized, controlled trial with long-term follow-up that included a highly selected group of people with HIV-1 infection.